FK-866

FK-866

CAT N°: 13287
Price:

From 163.00 138.55

FK-866 is a highly specific non-competitive inhibitor of Nampt (Ki = 0.4 nM), causing gradual NAD+ depletion.{17256} In HepG2 human liver carcinoma cells, NAD+ depletion by FK-866 directs delayed cell death by apoptosis (IC50 = ~1 nM).{17256} In normal human smooth muscle cells, FK-866 causes premature senescence, an effect that may be linked to decreased activity of the NAD+-dependent enzyme SIRT1.{17254} Also, FK-866 induces autophagy in SH-SY5Y neuroblastoma cells, as indicated by the formation of LC3-positive vesicles.{17255}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide
  • Correlated keywords
    • nicotinamides phosphoribosyltransferase NAMPT NamPRT PBEF visfatin mononucleotides adenine dinucleotide NAD+ inhibitors inhibitis inhibition cancers apoptosis SIRT1 autophagy FK866 FK 866 K22.175 K 22175 K22175 NamPRT PBEF visfatin carcinoma cells autophagy
  • Product Overview:
    FK-866 is a highly specific non-competitive inhibitor of Nampt (Ki = 0.4 nM), causing gradual NAD+ depletion.{17256} In HepG2 human liver carcinoma cells, NAD+ depletion by FK-866 directs delayed cell death by apoptosis (IC50 = ~1 nM).{17256} In normal human smooth muscle cells, FK-866 causes premature senescence, an effect that may be linked to decreased activity of the NAD+-dependent enzyme SIRT1.{17254} Also, FK-866 induces autophagy in SH-SY5Y neuroblastoma cells, as indicated by the formation of LC3-positive vesicles.{17255}

We also advise you